miR‑184 delays cell proliferation, migration and invasion in prostate cancer by directly suppressing DLX1

Tan,Gui-Geng; Xu,Chang; Zhong,Wei-Kang; Wang,Chuan-Yun

doi:10.3892/etm.2021.10597

miR‑184 delays cell proliferation, migration and invasion in prostate cancer by directly suppressing DLX1

Authors:
- Gui-Geng Tan
- Chang Xu
- Wei-Kang Zhong
- Chuan-Yun Wang
View Affiliations

Affiliations: Department of Urology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272100, P.R. China, Department of Urology, Yanzhou People's Hospital, Jining, Shandong 272100, P.R. China, Operating Room Department, Affiliated Hospital of Jining Medical University, Jining, Shandong 272100, P.R. China, Department of Urinary Surgery, Jining No. 1 People's Hospital, Jining, Shandong 272011, P.R. China
Published online on: August 11, 2021 https://doi.org/10.3892/etm.2021.10597
Article Number: 1163
Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of previous studies have reported that dysregulated miR‑184 expression is associated with the development of cancer. The aim of the present study was to investigate the role of miR‑184 in prostate cancer (PC) and the mechanism underlying its effects. Data from human tumor tissue samples were collected from The CEancer Genome Atlas to determine the expression levels of miR‑184 and DLX1. The miR‑184 mimic and pcDNA3.1‑DLX1 plasmid were utilized to induce overexpression of miR‑184 and DLX1 in Du145 cells, respectively. Cell Counting Kit‑8, wound healing and Transwell assays were performed to examine the effects of miR‑184 on the aggressiveness of PC cells. Dual‑luciferase reporter gene assay was used to investigate the association between miR‑184 and DLX1, and reverse transcription‑quantitative PCR and western blot analyses were utilized to determine the mRNA and protein levels. miR‑184 expression was found to be downregulated whereas DLX1 was upregulated in PC tissues compared with normal prostate tissues. Cell propagation, migration and invasion were all inhibited by miR‑184 upregulation in Du145 cells. Dual luciferase reporter assay confirmed the association between miR‑184 and DLX1. The inhibitory effect of miR‑184 mimic on cell behaviors was reversed by upregulation of DLX1. These findings suggest that miR‑184 plays a beneficial role in suppressing the tumorigenesis of PC by directly targeting DLX1, and it may represent a potential therapeutic strategy for PC.

View Figures

View References

1	Cancer Stat Facts: Prostate Cancer in 2018; Available from: https://seer.cancer.gov/statfacts/html/prost.html.
2	World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.11.
3	Caini S, Gandini S, Dudas M, Bremer V, Severi E and Gherasim A: Sexually transmitted infections and prostate cancer risk: A systematic review and meta-analysis. Cancer Epidemiol. 38:329–338. 2014.PubMed/NCBI View Article : Google Scholar
4	Miller DC, Hafez KS, Stewart A, Montie JE and Wei JT: Prostate carcinoma presentation, diagnosis, and staging: An update form the national cancer data base. Cancer. 98:1169–1178. 2003.PubMed/NCBI View Article : Google Scholar
5	Redman JM, Gulley JL and Madan RA: Combining immunotherapies for the treatment of prostate cancer. Urol Oncol. 35:694–700. 2017.PubMed/NCBI View Article : Google Scholar
6	Jang TL, Kim IY, Scardino PT and Eastham JA: Reply to effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today? Cancer. 125:2318–2320. 2019.PubMed/NCBI View Article : Google Scholar
7	Iorio MV and Croce CM: MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 4:143–159. 2012.PubMed/NCBI View Article : Google Scholar
8	Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol. 17:118–126. 2007.PubMed/NCBI View Article : Google Scholar
9	O'Hara SP, Mott JL, Splinter PL, Gores GJ and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional gene expression. Gastroenterology. 136:17–25. 2009.PubMed/NCBI View Article : Google Scholar
10	Wang XJ, Reyes JL, Chua NH and Gaasterland T: Prediction and identification of arabidopsis thaliana microRNAs and their mRNA targets. Genome Biol. 5(R65)2004.PubMed/NCBI View Article : Google Scholar
11	He J, Sun M, Geng H and Tian S: Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p. Biol Cell. 111:39–50. 2019.PubMed/NCBI View Article : Google Scholar
12	Liang YK, Han ZD, Lu JM, Liu ZZ, Zhuo YJ, Zhu XJ, Chen JX, Ye JH, Liang YX, He HC and Zhong WD: Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer. J Cell Biochem. 119:7245–7255. 2018.PubMed/NCBI View Article : Google Scholar
13	Jiang W, Gao Y, Wang Z, Gong C, Hu C, Ding X, Qiang L, Gao S and Ren F: Co-delivery of miR-4638-5p and docetaxel based on redox-sensitive polypeptide micelles as an improved strategy for the treatment of castration-resistant prostate cancer. Mol Pharm. 16:437–447. 2019.PubMed/NCBI View Article : Google Scholar
14	Khorasani M, Teimoori-Toolabi L, Farivar TN, Asgari M, Abolhasani M, Shahrokh H, Afgar A, Kalantari E, Peymani A and Mahdian R: Aberrant expression of miR-141 and nuclear receptor small heterodimer partner in clinical samples of prostate cancer. Cancer Biomark. 22:19–28. 2018.PubMed/NCBI View Article : Google Scholar
15	Aboobaker AA, Tomancak P, Patel N, Rubin GM and Lai EC: Drosophila microRNAs exhibit diverse spatial expression patterns during embryonic development. Proc Natl Acad Sci USA. 102:18017–18022. 2005.PubMed/NCBI View Article : Google Scholar
16	Wu X, Ding X, Ding Z and Jia P: Total flavonoids from leaves of carya cathayensis ameliorate renal fibrosis via the miR-21/Smad7 signaling pathway. Cell Physiol Biochem. 49:1551–1563. 2018.PubMed/NCBI View Article : Google Scholar
17	Wu G, Liu J, Wu Z, Wu X and Yao X: MicroRNA-184 inhibits cell proliferation and metastasis in human colorectal cancer by directly targeting IGF-1R. Oncol Lett. 14:3215–3222. 2017.PubMed/NCBI View Article : Google Scholar
18	Fang Z, Zhao J, Xie W, Sun Q, Wang H and Qiao B: LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by suppressing miR-184 expression. Cancer Med. 6:2897–2908. 2017.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Qadir M and Faheem A: mRNA: A diagnostic and therapeutic tool for pancreatic cnacer. Crit Rev Eukaryot Gene Expr. 27:197–204. 2017.PubMed/NCBI View Article : Google Scholar
21	Liang M, Sun Y, Yang HL, Zhang B, Wen J and Shi BK: DLX1, a binding protein of beta-catenin, promoted the growth and migration of prostate cancer cells. Exp Cell Res. 363:26–32. 2018.PubMed/NCBI View Article : Google Scholar
22	Li JY, Wei X, Sun Q, Zhao XQ, Zheng CY, Bai CX, Du J, Zhang Z, Zhu LG and Jia YS: MicroRNA-449b-5p promotes the progression of osteoporosis by inhibiting osteogenic differentiation of BMSCs via targeting Satb2. Eur Rev Med Pharmacol Sci. 23:6394–6403. 2019.PubMed/NCBI View Article : Google Scholar
23	Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et al: Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.PubMed/NCBI View Article : Google Scholar
24	Akao Y, Nakagawa Y and Naoe T: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 16:845–850. 2006.PubMed/NCBI
25	Neilson JR, Zheng GX, Burge CB and Sharp PA: Dynamic regulation of miRNA expression in ordered stages of cellular development. Genes Dev. 21:578–589. 2007.PubMed/NCBI View Article : Google Scholar
26	Chen XM, Splinter PL, O'Hara SP and LaRusso NF: A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against cryptosporidium parvum infection. J Biol Chem. 282:28929–28938. 2007.PubMed/NCBI View Article : Google Scholar
27	Su Z, Chen D, Li Y, Zhang E, Yu Z, Chen T, Jiang Z, Ni L, Yang S, Gui Y, et al: microRNA-184 functions as tumor suppressor in renal cell carcinoma. Exp Ther Med. 9:961–966. 2015.PubMed/NCBI View Article : Google Scholar
28	Feng L, Ma J, Ji H, Liu Y and Hu W: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2. Pathol Oncol Res. 24:853–860. 2018.PubMed/NCBI View Article : Google Scholar
29	Phua YW, Nguyen A, Roden DL, Elsworth B, Deng N, Nikolic I, Yang J, Mcfarland A, Russell R, Kaplan W, et al: MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Res. 17(83)2015.PubMed/NCBI View Article : Google Scholar
30	Chen D, Li J, Li S, Han P, Li N, Wang Y and Du S: miR-184 promotes cell proliferation in tongue squamous cell carcinoma by targeting SOX7. Oncol Lett. 16:2221–2228. 2018.PubMed/NCBI View Article : Google Scholar
31	Schneider JA and Logan SK: Revisiting the role of Wnt/β-catenin signaling in prostate cancer. Mol Cell Endocrinol. 462:3–8. 2018.PubMed/NCBI View Article : Google Scholar
32	Chan DW, Hui WW, Wang JJ, Yung MMH, Hui LMN, Qin Y, Liang RR, Leung THY, Xu D, Chan KKL, et al: DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling. Oncogene. 36:1404–1416. 2017.PubMed/NCBI View Article : Google Scholar
33	Sabóia TM, Reis MF, Martins AM, Romanos HF, Tannure PN, Granjeiro JM, Vieira AR, Antunes LS, Küchler EC and Costa MC: DLX1 and MMP3 contribute to oral clefts with and without positive family history of cancer. Arch Oral Biol. 60:223–228. 2015.PubMed/NCBI View Article : Google Scholar
34	Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, et al: Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin Cancer Res. 21:3061–3070. 2015.PubMed/NCBI View Article : Google Scholar
35	Rhie SK, Guo Y, Tak YG, Yao L, Shen H, Coetzee GA, Laird PW and Farnham PJ: Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits. Epigenetics Chromatin. 9(50)2016.PubMed/NCBI View Article : Google Scholar